Immunwork, Inc. was founded in October 2014. We focus on the research, development, and commercialization of a series of new drugs, which have been created based on our proprietary technology platform, to treat autoimmune diseases, multiple types of cancer, osteoporosis, and other selected severe diseases.Our technology platform enables us to design a class of new pharmaceuticals, which we term “T-E pharmaceuticals”. These new pharmaceuticals contain two functional moieties: a targeting (T) moiety and an effector (E) moiety. The invention of this drug-design platform was made by Dr. Tse-Wen Chang and his team, while they were working at the Genomic Research Center, Academic Sinica in Taipei, Taiwan. Immunwork acquired the licensing rights of the inventions, which are under patent applications, from Academia Sinica in 2015. Immunwork has been expanding the scope of the technology platform and developing its new applications. The drug-design platform can be employed for constructing antibody-drug conjugates (ADCs), bispecific antibodies, multivalent antibodies, and other pharmaceutical configurations.
Immunwork, Inc. was founded in October 2014. We focus on the research, development, and commercialization of a series of new drugs, which have been created based on our proprietary technology platform, to treat autoimmune diseases, multiple types of cancer, osteoporosis, and other selected severe diseases.Our technology platform enables us to design a class of new pharmaceuticals, which we term “T-E pharmaceuticals”. These new pharmaceuticals contain two functional moieties: a targeting (T) moiety and an effector (E) moiety. The invention of this drug-design platform was made by Dr. Tse-Wen Chang and his team, while they were working at the Genomic Research Center, Academic Sinica in Taipei, Taiwan. Immunwork acquired the licensing rights of the inventions, which are under patent applications, from Academia Sinica in 2015. Immunwork has been expanding the scope of the technology platform and developing its new applications. The drug-design platform can be employed for constructing antibody-drug conjugates (ADCs), bispecific antibodies, multivalent antibodies, and other pharmaceutical configurations.
